Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial

三氧化二砷 急性早幼粒细胞白血病 医学 维甲酸 化疗 随机对照试验 内科学 肿瘤科 维甲酸 癌症研究 砷 生物化学 基因 化学 冶金 材料科学
作者
Uwe Platzbecker,Giuseppe Avvisati,Laura Cicconi,Christian Thiede,Francesca Paola Paoloni,Marco Vignetti,Felicetto Ferrara,Mariadomenica Divona,Francesco Albano,Fabio Efficace,Paola Fazi,Marco Sborgia,Eros Di Bona,Massimo Breccia,Erika Borlenghi,Roberto Cairoli,Alessandro Rambaldi,Lorella Maria Antonia Melillo,Giorgio La Nasa,Walter Fiedler
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:35 (6): 605-612 被引量:416
标识
DOI:10.1200/jco.2016.67.1982
摘要

Purpose The initial results of the APL0406 trial showed that the combination of all- trans-retinoic acid (ATRA) and arsenic trioxide (ATO) is at least not inferior to standard ATRA and chemotherapy (CHT) in first-line therapy of low- or intermediate-risk acute promyelocytic leukemia (APL). We herein report the final analysis on the complete series of patients enrolled onto this trial. Patients and Methods The APL0406 study was a prospective, randomized, multicenter, open-label, phase III noninferiority trial. Eligible patients were adults between 18 and 71 years of age with newly diagnosed, low- or intermediate-risk APL (WBC at diagnosis ≤ 10 × 10 9 /L). Overall, 276 patients were randomly assigned to receive ATRA-ATO or ATRA-CHT between October 2007 and January 2013. Results Of 263 patients evaluable for response to induction, 127 (100%) of 127 patients and 132 (97%) of 136 patients achieved complete remission (CR) in the ATRA-ATO and ATRA-CHT arms, respectively ( P = .12). After a median follow-up of 40.6 months, the event-free survival, cumulative incidence of relapse, and overall survival at 50 months for patients in the ATRA-ATO versus ATRA-CHT arms were 97.3% v 80%, 1.9% v 13.9%, and 99.2% v 92.6%, respectively ( P < .001, P = .0013, and P = .0073, respectively). Postinduction events included two relapses and one death in CR in the ATRA-ATO arm and two instances of molecular resistance after third consolidation, 15 relapses, and five deaths in CR in the ATRA-CHT arm. Two patients in the ATRA-CHT arm developed a therapy-related myeloid neoplasm. Conclusion These results show that the advantages of ATRA-ATO over ATRA-CHT increase over time and that there is significantly greater and more sustained antileukemic efficacy of ATO-ATRA compared with ATRA-CHT in low- and intermediate-risk APL.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小凯完成签到 ,获得积分10
1秒前
1秒前
1秒前
1秒前
szxa发布了新的文献求助10
1秒前
KEKEKE发布了新的文献求助10
2秒前
Lee发布了新的文献求助10
3秒前
无味完成签到,获得积分10
3秒前
传奇3的应助被昏昏欲睡采纳,获得10
3秒前
CarryLJR的应助被梧桐雨210采纳,获得10
4秒前
初景发布了新的文献求助10
4秒前
lyt完成签到,获得积分10
4秒前
科研研通发布了新的文献求助10
4秒前
丘比特的应助被mn采纳,获得10
5秒前
5秒前
5秒前
6秒前
斯文败类的应助被KTV采纳,获得10
6秒前
FOB发布了新的文献求助10
6秒前
LJXX发布了新的文献求助10
6秒前
大模型的应助被HBB采纳,获得10
6秒前
Franklin发布了新的文献求助10
6秒前
6秒前
syvshc的应助被李周采纳,获得10
6秒前
大模型的应助被玩家666采纳,获得10
7秒前
8秒前
生动亦云完成签到,获得积分20
8秒前
辣爆虾尾完成签到 ,获得积分10
8秒前
9秒前
杨瑞超发布了新的文献求助10
9秒前
9秒前
小二郎的应助被飞快的枕头采纳,获得10
10秒前
11秒前
李海木糖完成签到,获得积分10
12秒前
FOB完成签到,获得积分10
12秒前
斯多姆发布了新的文献求助10
13秒前
13秒前
BPX发布了新的文献求助10
13秒前
orixero的应助被快乐水采纳,获得10
13秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178866
求助须知:如何正确求助?哪些是违规求助? 9569638
关于积分的说明 21805411
捐赠科研通 7774048
什么是DOI,文献DOI怎么找? 3432955
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478628